AMAZE™ Asthma Implementation Quality Improvement Study
18 Years +
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Jul 2022 by AstraZeneca
Greater Austin Allergy, Evidera, Inc.
No locations available
Each participant will be asked to complete the symptoms log daily for up to 6 months. Additional surveys will be completed throughout the study by participants and GAA clinical staff.